Rationale and design for an investigation to optimize selective serotonin reuptake inhibitor treatment for pregnant women with depression

M. J. Avram, C. S. Stika, L. J. Rasmussen-Torvik, J. D. Ciolino, E. Pinheiro, A. L. George, K. L. Wisner*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

The physiological changes of pregnancy can affect the pharmacokinetics of a drug, thereby affecting its dose requirements. Because pharmacokinetic (PK) studies in pregnant women have rarely been conducted, evidence-based dosing adjustments are seldom available. In particular, despite the fact that the use of antidepressants has become increasingly common, pregnancy-associated PK changes of the selective serotonin reuptake inhibitors (SSRIs) are largely unknown.

Original languageEnglish (US)
Pages (from-to)31-33
Number of pages3
JournalClinical pharmacology and therapeutics
Volume100
Issue number1
DOIs
StatePublished - Jul 1 2016

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Rationale and design for an investigation to optimize selective serotonin reuptake inhibitor treatment for pregnant women with depression'. Together they form a unique fingerprint.

Cite this